Thomas Jensen

Company: Allarity Therapeutics A/S

Job title: Chief Executive Officer

Seminars:

Enhancing Patient Selection in Oncology: Clinical Validation of a Multi-Gene Expression Diagnostic 2:15 pm

 Introduction to Allarity’s Drug Response Predictor (DRP)- a multi-gene expression diagnostic for selecting patients likely to benefit from cancer therapies Key findings from the phase II ddvanced, recurrent ovarian cancer study showcasing the impact of Allarity’s novel PARP/ Tankyrase inhibitor, Stenoparib A discussion of Stenoparib’s potential in advanced ovarian cancer using the Stenoparib DRP to…Read more

day: Day Three Track B